Second, we used targeted treatments directed at the androgen receptor (AR), which is intrinsically linked to PI3K pathway signaling in prostate cancer and whereby AR inhibition leads to an up-regulation of AKT activity via suppression of the AKT phosphatase PHLPP (37). The gene discussed is AKT1; the disease is prostate carcinoma.